


PTO/SB/08A (08-03)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/759,337
		Filing Date	January 16, 2004
		First Named Inventor	Tidmarsh, George
		Art Unit	1614
		Examiner Name	Raymond J. Henley III
Sheet 1 of 2	Attorney Docket Number	021305-003500US	

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
[Signature]	AA	US-3,895,026	07-15-1975	PALAZZO et al.	
	AB	US-5,827,887	10-27-1998	GOURVEST et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (If known)				
	AC	WO	98/10781	A1	03-19-1998	Asta Medica		<input type="checkbox"/>
	AD	WO	97/14670	A1	04-24-1997	Kanoldt Arzneimittel		<input type="checkbox"/>
	AE	WO	96/40142	A1	12-19-1996	Pfizer, Inc.		<input type="checkbox"/>
	AF	WO	2004/064735	A2	08-05-2004	Threshold Pharmaceuticals		<input type="checkbox"/>
	AG	WO	2004/064736	A2	08-05-2004	Threshold Pharmaceuticals		<input type="checkbox"/>
	AH	CA	2,206,198		05-27-1997	Hoechst Aktiengesellschaft		<input type="checkbox"/>
	AI	IE	54256		08-02-1989	A.C.R.A.F.		<input type="checkbox"/>

Examiner Signature		Date Considered	6/20/05
-----------------------	--	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

60509612 v1

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/759,337
				Filing Date	January 16, 2004
				First Named Inventor	Tidmarsh, George
				Art Unit	1614
				Examiner Name	Raymond J. Henley III
Sheet	2	of	2	Attorney Docket Number	021305-003500US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AJ	ISAACS et al., "Etiology and disease process of benign prostatic hyperplasia" <u>Prostate Suppl.</u> , 2:33-50 (1989).	
	AK	HUDSON et al., "Proliferative heterogeneity in the human prostate: evidence for epithelial stem cells" <u>Lab Invest.</u> , 80:1243-1250 (2000).	
	AL	COLLINS et al., "Benign prostatic stromal cells are regulated by basic fibroblast growth factor and transforming growth factor-beta 1" <u>J Endocrinol.</u> , 151:315-322 (1996).	
	AM	GIRI et al., "Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia" <u>Am J Pathol.</u> , 159:139-147 (2001).	
	AN	CASTRO et al., "Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia" <u>Prostate</u> , 60:153-159 (2004).	
	AO	BOCCARDO et al., "Phase II study with lonidamine in the treatment of hormone-refractory prostatic cancer patients" <u>Tumori</u> , 78:137-139 (1992).	
	AP	DUDAK et al., "Enhancement of radiation response of prostatic carcinoma by lonidamine" <u>Anticancer Res.</u> , 16:3665-3671 (1996).	
	AQ	BLOCH et al., "Enhancement of hyperthermic toxicity by lonidamine in the Dunning R3327G rat prostatic adenocarcinoma" <u>Prostate</u> , 24:131-138 (1994).	
	AR	BENZ et al., "Lactic dehydrogenase isozymes, 31P magnetic resonance spectroscopy, and in vitro, antimitochondrial tumor toxicity with gossypol and rhodamine-123," <u>J Clin Invest.</u> 79:517-523. (1987)	
	AS	ERI et al., "Effects on the endocrine system of long-term treatment with the luteinizing hormone-releasing hormone agonist leuprolide in patients with benign prostatic hyperplasia" <u>Scandinavian Journal of Clinical and Laboratory Investigation</u> , 56: 319-325 (1996).	
	AT	International Search Report and Written Opinion for PCT/US2004/001141 (WO 2004/064735) (9/22/04)	
	AU	International Search Report and Written Opinion for PCT/US2004/001146 (WO 2004/064736) (3/1/05)	
	AV	LOBL, 1979, "1-(2,4-Dichlorobenzyl)-1H-Indazole-3-Carboxylic Acid (DICA), an Exfoliative Antispermatic Agent in the Rat" <u>Arch Andrology</u> 2:353-63 (1979)	
AW	SHIDAIFAT et al, 1997, "Gossypol arrests human benign prostatic hyperplastic cell growth at G0/G1 phase of the cell cycle" <u>Anticancer Res.</u> 17:1003-9.		
AX	CHANG, 1997, "Gossypol induces spermidine/spermine N1-acetyltransferase in canine prostate epithelial cells" <u>Biochem Biophys Res Commun.</u> 231:383-8.		

Examiner Signature		Date Considered	6/20/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.